This is a renewal application for support of the Yale University Digestive Disease Research Core Center, a multidisciplinary Center whose research focus is Liver Structure, Function and Disease. Fifty seven independently funded investigators comprise a current digestive disease related research base of ~ $32 million. Research programs in the Center are distributed in 15 departments of the University including Biomedical Engineering;Cell Biology;Cellular and Molecular Physiology;Comparative Medicine;Epidemiology and Public Health;Human Genetics;Immunobiology;Internal Medicine;Microbial Pathogenesis;Molecular, Cellular and Developmental Biology;Pathology;Pediatrics;Pharmacology;Radiology and Surgery. The research base continues to focus on six major areas: 1) Cellular and Molecular Biology of the Liver. 2) Hepatic Transport Mechanisms. 3) Basic Biology of Disease Processes. 4) Cirrhosis and its Complications. 5) Liver Immunology and 6) Clinical Hepatology. The research programs are broad and range from fundamental studies of the biology of liver and related digestive systems to translational studies of immediate clinical relevance. The major goals of the Center continue to be: 1) to stimulate multidisciplinary interactions between basic and clinical faculty and departments, 2) to provide an in-depth training environment, 3) to efficiently organize time consuming, often costly techniques and procedures in Core Facilities for use by multiple investigators, 4) to stimulate basic scientists to direct their focus to areas of interest to the Center, 5) to stimulate translational research from bench to bedside, 6) to promote new research and training opportunities with a pilot feasibility program, and 7) to create an intellectual environment within the field by fostering collaborations both within and outside the institution and through its enrichment program. To achieve these goals the Center is organized into 4 Core Facilities including: 1) Administrative Core 2) Cellular and Molecular Physiology Core 3) Morphology Core and 4) A Clinical Translational Core. A Pilot Feasibility Program supports 1-2 year small grants for new scientific, initiatives. The Enrichment Program consists of research seminars, symposia, and retreats.
The Yale Liver Center's mission is to enhance knowledge of the etiology, diagnosis and treatment of liver diseases and other related disorders of the digestive system, thereby advancing the nation's public health. It does so by simulating both basic and clinical research in this discipline at the University and by establishing core research facilities for use by multiple investigators.
|Tran, Melanie; Lee, Sang-Min; Shin, Dong-Ju et al. (2017) Loss of miR-141/200c ameliorates hepatic steatosis and inflammation by reprogramming multiple signaling pathways in NASH. JCI Insight 2:|
|Cai, Shi-Ying; Boyer, James L (2017) Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury. Inflamm Cell Signal 4:|
|Yang, An-Ming; Inamine, Tatsuo; Hochrath, Katrin et al. (2017) Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest 127:2829-2841|
|Park, Jin-Kyu; Shao, Mingjie; Kim, Moon Young et al. (2017) An endoplasmic reticulum protein, Nogo-B, facilitates alcoholic liver disease through regulation of kupffer cell polarization. Hepatology 65:1720-1734|
|Yu, Dongke; Zhang, Han; Lionarons, Daniel A et al. (2017) Na+-taurocholate cotransporting polypeptide (NTCP/SLC10A1) ortholog in the marine skate Leucoraja erinacea is not a physiological bile salt transporter. Am J Physiol Regul Integr Comp Physiol 312:R477-R484|
|Jangouk, Parastoo; Turco, Laura; De Oliveira, Ana et al. (2017) Validating, deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis. Liver Int 37:1177-1183|
|Assis, David N; Abdelghany, Osama; Cai, Shi-Ying et al. (2017) Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. J Clin Gastroenterol 51:e11-e16|
|Yu, Ai-Ming; Ingelman-Sundberg, Magnus; Cherrington, Nathan J et al. (2017) Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharm Sin B 7:241-248|
|Tran, Melanie; Wang, Li (2017) Preserving LXR by inhibiting T39: A step closer to treating atherosclerosis and steatohepatitis? Hepatology 65:741-744|
|Feriod, Colleen N; Oliveira, Andre Gustavo; Guerra, Mateus T et al. (2017) Hepatic Inositol 1,4,5 Trisphosphate Receptor Type 1 Mediates Fatty Liver. Hepatol Commun 1:23-35|
Showing the most recent 10 out of 705 publications